

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number
WO 2004/027427 A1

- (51) International Patent Classification⁷: **G01N 33/566**, 66/74
- (74) Agent: **ASTRAZENECA AB**; Global Intellectual Property, S-151 85 Sodertälje (SE).
- (21) International Application Number:
PCT/GB2003/004132
- (22) International Filing Date:
19 September 2003 (19.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/412,026 19 September 2002 (19.09.2002) US
- (71) Applicant (*for all designated States except US*): **ASTRAZENECA AB** [SE/SE]; S-151 85 Sodertälje (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **HENDERSON, Duncan** [GB/SE]; AstraZeneca AB, S-151 85 Sodertälje (SE). **SALTER, Sylvia** [GB/SE]; AstraZeneca AB, S-151 85 Sodertälje (SE). **ELAGOZ, Aram** [CA/CA]; AstraZeneca AB, S-151 85 Sodertälje (SE). **GRAZZINI, Eric** [CA/CA]; AstraZeneca AB, S-151 85 Sodertälje (SE). **LEMBO, Paola, M., C.** [CA/CA]; AstraZeneca AB, S-151 85 Sodertälje (SE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- *with international search report*
 - *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **ASSAYS FOR FPRL-1 LIGANDS**

(57) Abstract: Assays for screening for compounds that act as agonists, antagonists, or inverse agonists of CK β 8-1 at the FPRL-1 receptor.

WO 2004/027427 A1

ASSAYS FOR FPRL-1 LIGANDS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit under 35 U.S.C. §119(e) of U.S. Provisional Application 60/412,026, filed September 19, 2002, incorporated herein by reference.

FIELD OF THE INVENTION

[0001] The present invention relates to screening assays for compounds that modulate the interaction between CK β 8-1 and the FPRL-1 receptor.

BACKGROUND

[0002] CK β 8, or myeloid progenitor inhibitor factor-1 (MPIF-1), is a CC chemokine (MacPhee *et al.*, 1998, J. Immunol., 161:6273; Youn *et al.*, 1998, Blood, 91:3118). CK β 8 cDNA encodes a signal sequence of 21 amino acids followed by 99 amino acid residues (CK β 8 protein) or 116 amino acid residues (CK β 8-1 protein). CK β 8-1 is a splice variant form of CK β 8. CK β 8 activates monocytes, eosinophils, neutrophils, osteoclast precursors and lymphocytes. It also causes suppression of colony formation by progenitor cells found in human bone marrow. CK β 8 and CK β 8-1 are known to mediate some of their effects by activation via the CCR1 receptor.

[0003] G protein coupled receptors (GPCRs) constitute a family of proteins sharing a common structural organization characterized by an extracellular N-terminal end, seven hydrophobic alpha helices putatively constituting transmembrane domains and an intracellular C-terminal domain. GPCRs bind a wide variety of ligands that trigger intracellular signals through the activation of transducing G proteins (Caron *et al.*, 1993, Rec. Prog. Horm. Res., 48:277-290; Freedman *et al.*, 1996, Rec. Prog. Horm. Res., 51:319-353).

[0004] More than 300 GPCRs have been cloned thus far. Roughly 50-60% of all clinically relevant drugs are thought to act by modulating the functions of various GPCRs (Gudermann *et al.*, 1995, J. Mol. Med., 73:51-63).

[0005] Among the GPCRs that have been identified and cloned is the formyl peptide receptor-like-1 (FPRL-1) receptor (Murphy *et al.*, 1992, J. Biol Chem, 267:7637; Ye *et al.*, 1992, Biochem. Biophys. Res. Comm., 184:582. This has been reported to be a low potency formyl-peptide receptor and a receptor for Lipoxin A4 and several other ligands (Klein *et al.*, 1998, Nature Biotechnology, 16:1334-1337; Le *et al.*, 2002, Int. Immunopharmacol., 2:1-13).

SUMMARY

[0006] The present invention provides methods for identifying compounds that modulate the binding of CK β 8-1 to the FPRL-1 receptor comprising providing cells that express FPRL-1 receptor, or a functional fragment or variant thereof, contacting the cells with CK β 8-1, or a functional fragment or variant thereof, in the presence or absence of a test compound, and measuring a signal that is indicative of receptor activation, wherein an alteration to the signal in the presence of a compound identifies the tested compound as a compound that modulates the binding of CK β 8-1 to the FPRL-1 receptor.

[0007] The present invention also provides methods for identifying compounds that modulate the binding of CK β 8-1 to the FPRL-1 receptor comprising providing the FPRL-1 receptor or functional fragment or variant thereof, contacting the FPRL-1 receptor, or functional fragment or variant thereof, with CK β 8-1 or functional fragment or variant thereof in the presence or absence of a test compound, and measuring the amount of CK β 8-1 or functional fragment or variant thereof that forms a complex with the FPRL-1 receptor or functional fragment or variant thereof, wherein an alteration to the amount of the complex formed in the presence of the test compound identifies the compound as a compound that modulates binding of CK β 8-1 to FPRL-1 receptor.

[0008] The present invention also provides methods of distinguishing a FPRL-1 receptor agonist or antagonist comprising measuring a cell stimulating activity through a FPRL-1 receptor determined from contacting a compound with a cell expressing a FPRL-1 receptor or functional fragment or variant thereof (test screen), and comparing the results to a control screen wherein the cell does not express the FPRL-1 receptor or functional fragment or variant thereof, wherein said compound having cell stimulating activity in the test screen but not the control screen indicates that the test compound is a FPRL-1 receptor agonist, and contacting CK β 8-1 or functional fragment or variant thereof and a test compound with a cell expressing a FPRL-1 receptor or functional fragment or variant thereof (test screen), and comparing the results to a control screen wherein the cell does not express the FPRL-1

receptor or functional fragment or variant thereof, wherein a decrease in cell stimulating activity by CK β 8-1 or functional fragment or variant thereof in the test screen but not the control screen indicates that the test compound is a FPRL-1 receptor antagonist.

[0009] The invention also provides methods of screening for compounds that modulate binding of CK β 8-1 to the FPRL-1 receptor, comprising comparing the amount of CK β 8-1 or functional fragment or variant thereof bound to FPRL-1 receptor or functional fragment or variant thereof in steps (a) and (b), where step (a) comprises contacting CK β 8-1 or functional fragment or variant thereof with the FPRL-1 receptor or functional fragment or variant thereof, and step (b) comprises contacting CK β 8-1 or functional fragment or variant thereof and a test compound with the FPRL-1 receptor or functional fragment or variant thereof, wherein an alteration in the amount of CK β 8-1 or functional fragment or variant thereof bound to FPRL-1 receptor or functional fragment or variant thereof in step (b) indicates that the test compound modulates the binding of CK β 8-1 to the FPRL-1 receptor.

[0010] The invention also provides methods of screening for compounds that inhibit binding of CK β 8-1 to FPRL-1 receptor, comprising comparing the amount of CK β 8-1 or functional fragment or variant thereof bound to FPRL-1 receptor or functional fragment or variant thereof in steps (a) and (b), where step (a) comprises contacting CK β 8-1 or functional fragment or variant thereof with the FPRL-1 receptor or functional fragment or variant thereof, and step (b) comprises contacting CK β 8-1 or functional fragment or variant thereof and a test compound with the FPRL-1 receptor or functional fragment or variant thereof, wherein a decrease in CK β 8-1 or functional fragment or variant thereof binding in step (b) indicates that the test compound inhibits binding of CK β 8-1 to the FPRL-1 receptor.

[0011] The invention also provides methods of identifying a compound that modulates binding of CK β 8-1 to FPRL-1 receptor, comprising contacting FPRL-1 receptor or functional fragment or variant thereof with CK β 8-1 or functional fragment or variant thereof in the presence or absence of a test compound, and comparing the amount of binding between CK β 8-1 or functional fragment or variant thereof and the FPRL-1 receptor or functional fragment or variant thereof in the presence or absence of the test compound, wherein an alteration in the amount of binding between CK β 8-1 or functional fragment or variant thereof and the FPRL-1 receptor or functional fragment or variant thereof in the presence of the test compound indicates that the test compound modulates binding between CK β 8-1 and the FPRL-1 receptor.

[0012] The invention also provides methods of identifying compounds that can bind to the FPRL-1 receptor, comprising incubating a cell expressing the FPRL-1 receptor or functional fragment or variant thereof with CK β 8-1 or functional fragment or variant thereof in the presence or absence of a compound, and detecting displacement of CK β 8-1 or functional fragment or variant thereof binding to the FPRL-1 receptor or functional fragment or variant thereof in the presence of the compound, wherein the displacement is indicative of a compound that binds the FPRL-1 receptor.

[0013] The invention also provides methods of determining if a test compound is an agonist, antagonist or inverse agonist of CK β 8-1, comprising incubating a cell expressing FPRL-1 or functional fragment or variant thereof with the test compound, measuring a signal indicative of receptor activation and comparing the measurement with a second measurement of a signal indicative of receptor activation obtained from incubations performed in the absence of the test compound, wherein the test compound is determined to be an agonist of CK β 8-1 if the signal indicative of receptor activation is higher in the presence of the test compound than in its absence, and wherein the test compound is determined to be an antagonist of CK β 8-1 if the signal indicative of receptor activation is lower in the presence of the test compound than in its absence.

DETAILED DESCRIPTION

[0014] We have discovered that CK β 8-1 activates the FPRL-1 receptor at nanomolar concentrations and that the FPRL-1 receptor is coupled to the G protein G_{ai/o}. We have also discovered that CK β 8-1 selectively binds to FPRL-1 and induces chemotaxis of peripheral blood cells.

[0015] The interaction between CK β 8-1 and the FPRL-1 receptor can be harnessed in assays to identify compounds that modulate binding of CK β 8-1 and the FPRL-1 receptor, to identify compounds that modulate CK β 8-1 activation of the FPRL-1 receptor, and to identify compounds that are agonists, antagonists or inverse agonists of the FPRL-1 receptor. Compounds identified in such assays can be used as therapeutic agents in the treatment of inflammatory disorders and in Alzheimer's disease. Compounds that modulate the binding interaction between CK β 8-1 and the FPRL-1 receptor can be identified. Compounds that modulate the activation of the FPRL-1 receptor can be identified.

[0016] As used herein, the terms "modulate" or "modulates" in reference to binding include any measurable alteration to the binding interaction between CK β 8-1 to FPRL-1 receptor,

including, but not limited to, the amount or quantity of binding, binding affinity, and binding efficiency. For example, compounds identified using assays and methods of the present invention may increase or decrease the amount of binding of CK β 8-1 to the FPRL-1 receptor. Compounds identified using assays and methods of the present invention may enhance or inhibit the rate of binding of CK β 8-1 to FPRL-1 receptor.

[0017] As used herein, the term "inhibit" in reference to binding of CK β 8-1 to FPRL-1 receptor means any measurable decrease in binding.

[0018] As used herein, the term "decrease" in reference to cell stimulating activity or in reference to binding of CK β 8-1 to FPRL-1 receptor means any measurable diminution of such cell stimulating activity or binding activity.

[0019] As used herein, the term "increase" in reference to cell stimulating activity or in reference to binding of CK β 8-1 to FPRL-1 receptor means any measurable enhancement of such cell stimulating activity or binding activity.

[0020] As used herein, the terms "contact" or "contacting" refers to any method of combining components, such as combining compounds and/or CK β 8-1 in culture medium containing cells expressing the FPRL-1 receptor, or combining compounds and/or CK β 8-1 in solutions containing the FPRL-1 receptor, which may or may not be bound to a substrate.

[0021] As used herein, the phrase "functional fragment" in reference to CK β 8-1 protein, refers to portions or fragments of CK β 8-1 protein that are functionally active in the assays of the present invention, *i.e.*, are capable of binding to and/or activating the FPRL-1 receptor. Functional fragment also includes fusion proteins that contain portions of CK β 8-1 protein.

[0022] As used herein, the phrase "functional fragment" in reference to FPRL-1 receptor protein, refers to portions or fragments of FPRL-1 receptor protein that are functionally active in the assays of the present invention, *i.e.*, are capable of binding to and/or being activated by the CK β 8-1 protein. Functional fragment also includes fusion proteins that contain portions of FPRL-1 receptor.

[0023] As used herein, the term "variant" in reference to either CK β 8-1 protein or FPRL-1 receptor protein includes proteins having amino acid modifications, mutations, deletions, or insertions and other protein modifications that retain functionality in the assays of the present invention.

[0024] One skilled in the art can readily determine whether a protein or peptide is a functional fragment of CK β 8-1 or FPRL-1 receptor by examining its sequence and testing for binding and/or activation activity without undue experimentation. Truncated versions of

CK β 8-1 or FPRL-1 receptor and fusion proteins containing portions of CK β 8-1 or FPRL-1 receptor may be prepared and tested using routine methods and readily available starting material.

[0025] As used herein, the term "heterologous" in reference to the FPRL-1 receptor gene means any non-endogenous FPRL-1 receptor gene, for example, one that has been introduced or transfected into a cell, which includes FPRL-1 receptor genes from different species or organisms than the cell and recombinant FPRL-1 receptor genes from the same species or organism as the cell.

[0026] Examples of signals that can be measured in assays of the present invention and which serve as indicators of receptor activation or indicators of cell stimulating activity include, but are not limited to, intracellular phospholipase C (PLC) activity, phospholipase A (PLA) activity, adenylyl cyclase activity, neutrophil chemotaxis, intracellular concentration of calcium in the cell, and opening and closing of ion channels. Many other methods of measuring receptor activation and cell stimulation are known to those skilled in the art and can be used in the assays of the present invention.

[0027] One aspect of the present invention is directed to assays for screening for compounds with the ability to modulate the binding of CK β 8-1 to the human FPRL-1 receptor. In some embodiments, cells expressing FPRL-1 receptor are used in conjunction with CK β 8-1 in screening assays designed to identify compounds that modulate CK β 8-1/FPRL-1 binding. Cells expressing the FPRL-1 receptor can be incubated with CK β 8-1 and a test compound. The extent to which the binding of CK β 8-1 is displaced by the test compound is then determined. Radioligand assays or enzyme-linked immunosorbent assays may be performed in which either CK β 8-1 or the test compound is detectably labeled.

[0028] In some embodiments, cells expressing FPRL-1 receptor are used in assays to screen compounds that modulate CK β 8-1/FPRL-1 binding. Any cell type in which FPRL-1 receptor is expressed or can be engineered to be expressed can be used. Any cell type in which receptor binding and/or receptor activation can be measured may be used in the assays of the invention. By way of non-limiting examples, the assay may utilize mammalian cells (including, but not limited to, human, hamster, mouse, rat, or monkey) or non-mammalian cells such as amphibian (*e.g.*, frog) or fish cells. Cell lines that may be used in the assays of the invention include, but are not limited to, HEK-293s (human embryonic kidney), CHO (Chinese hamster ovary), LTK- (murine fibroblasts lacking cytosolic deoxythymidine kinase (dTK)), HeLa, BALB/c-3T3, *Xenopus* oocytes; melanophores (cells from fish and

amphibians) may also be used. In some embodiments, HEK-293s cells expressing the G protein $G_{\alpha 16}$ are used.

[0029] In some embodiments, a recombinant cell expressing a heterologous FPRL-1 receptor from a heterologous gene expression construct is used. Any species of FPRL-1 receptor may be used, including, but not limited to a mammalian FPRL-1 receptor, including human, rodent, murine, rat, guinea pig, mouse, hamster, rhesus, cynomolgous monkey, and porcine. The FPRL-1 receptor protein may be a fusion protein or may have variation in amino acid sequence, including deletions, insertions, mutations, and polymorphisms.

[0030] Another aspect of the invention relates to methods of determining if a test compound is an agonist, an antagonist, or an inverse agonist of CK β 8-1 binding based upon a functional assay. In some embodiments, assays are carried out by incubating a cell expressing FPRL-1 receptor with a test compound and determining whether intracellular phospholipase C activity, adenylyl cyclase activity, or intracellular calcium concentrations are modulated. Results can be compared with controls wherein incubations are performed in a similar manner but in the absence of the test compound. Functional assays of this type can be performed in conjunction with binding assays, including those described herein. In some embodiments, the cell used in functional assays is a recombinant cell that has been transformed with a heterologous FPRL-1 gene.

[0031] Inverse agonists reduce phospholipase C activity or intracellular calcium levels, particularly if assays are performed in the presence of a fixed amount of CK β 8-1. Antagonists block binding of CK β 8-1 to the receptor but do not produce the opposite response in terms of phospholipase C activity or intracellular calcium that is the hallmark of an inverse agonist.

[0032] In some embodiments of the invention, FPRL-1 is recombinantly expressed in cells from a heterogenous or heterologous gene. The FPRL-1 receptor can be cloned as described by Murphy *et al.*, 1992, *supra*. The FPRL-1 coding sequence can be incorporated into an expression vector with a promoter and other regulatory elements that will be active and appropriate for expression in the particular cell type used (*see*, Sambrook *et al.*, eds., Molecular Cloning: A Laboratory Manual (2nd ed.), Cold Spring Harbor: Laboratory Press, Cold Spring Harbor, NY (1989)). In some embodiments, mammalian cells are used. Examples of promoters that may be used for expression in mammalian cells, include, but are not limited to, the mouse metallothionein I gene promoter (Hamer *et al.*, 1982, J. Mol. Appl. Gen., 1:273-288), the immediate-early and TK promoter of herpes virus (Yao *et al.*, 1995, J. Virol., 69:6249-6258, McKnight, 1982, Cell, 31:355-365); the SV40 virus early promoter

(Benoist *et al.*, 1981, Nature, 290:304-310), and the CMV promoter (Boshart *et al.*, 1985, Cell, 41:521-530). Vectors may also include enhancers and other regulatory elements.

[0033] Expression vectors can be introduced into cells by methods well known to the art, including, but not limited to, calcium phosphate precipitation, microinjection, electroporation, liposomal transfer, viral transfer, or particle-mediated gene transfer.

[0034] In some embodiments the FPRL-1 receptor is used to screen for compounds that mimic the action of CK β 8-1 (agonists).

[0035] In some embodiments the FPRL-1 receptor is used to screen for compounds that antagonize the action of CK β 8-1 (antagonists).

[0036] In some embodiments the human FPRL-1 receptor is used.

[0037] In some embodiments human CK β 8-1 is used.

[0038] In some embodiments the form of CK β 8-1 that is used is the amino-terminally truncated form, CK β 8-1 (aa46-137).

[0039] Cells can be selected and assayed or examined for the expression of FPRL-1 according to standard procedures and techniques known to the art, including, but not limited to Northern blotting analysis.

[0040] In some embodiments, CK β 8-1 and cells expressing the FPRL-1 receptor are used in assays to determine whether test compounds have any effect on binding between CK β 8-1 and the FPRL-1 receptor. A wide variety of different types of assays can be performed using standard methods known to those of skill in the art. For example, in radioligand binding assays, cells expressing FPRL-1 are incubated with CK β 8-1 and with a compound being tested for binding activity. In some embodiments, the source of FPRL-1 is recombinantly transformed HEK-293s cells. In some embodiments, other cells types that do not express other proteins that strongly bind CK β 8-1 are utilized. Such cell types can easily be determined by performing binding assays on cells transformed with FPRL-1 and comparing the results obtained with those obtained using their non-transformed counterparts.

[0041] In some embodiments of the invention, functional assays, such as mobilization of intracellular calcium, are carried out using a FLIPR (Fluorescent Imaging Plate Reader) detection system.

[0042] In some embodiments of the invention, CK β 8-1 is iodinated and used as a tracer in radioligand binding assays on whole cells or membranes. Other assays that can be used include, but are not limited to, the GTP γ S assay, adenylyl cyclase assays, assays measuring

inositol phosphates, and reporter gene assays (*e.g.*, those utilizing luciferase, aequorin, alkaline phosphatase, etc.).

[0043] Assays may be performed using either intact cells or membranes prepared from the cells (see *e.g.*, Wang *et al.*, Proc. Natl. Acad. Sci. U.S.A. 90:10230-10234 (1993)). In some embodiments, membranes or whole cells are incubated with CK β 8-1 and with a preparation of the compound being tested. After binding is complete, the receptor is separated from the solution containing the ligand and test compound, *e.g.*, by filtration, and the amount of binding that has occurred is determined. In some embodiments, the ligand used is detectably labeled with a radioisotope such as, for example, ¹²⁵I. Other types of labels can also be used, including, but not limited to, the following fluorescent labeling compounds: fluorescein, isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin o-phthaldehyde and fluorescamine. Chemiluminescent compounds can also be used with the assays of the invention, including, but not limited to, luminol, isoluminol, thionin or acridinium ester, imidazole, acridinium salt, and oxalate ester.

[0044] In some embodiments of the invention, assays are performed in a cell-free environment, such as, for example, where only the binding interaction between CK β 8-1 and the FPRL-1 receptor is being examined. In such cell-free or *in vitro* binding assays FPRL-1 or CK β 8-1 may be bound to a support.

[0045] In some embodiments of the invention, assays are carried out wherein the compound is tested at different concentrations and the signal measured at these different concentrations permits the binding affinity of the compounds to be determined.

[0046] Nonspecific binding may be determined by carrying out the binding reaction in the presence of a large excess of unlabeled ligand. For example, labeled CK β 8-1 may be incubated with receptor and test compound in the presence of a thousand-fold excess of unlabeled CK β 8-1. Nonspecific binding should be subtracted from total binding, *i.e.*, binding in the absence of unlabeled ligand, to arrive at the specific binding for each sample tested. Other steps such as washing, stirring, shaking, filtering and the like may be included in the assays as necessary. Typically, wash steps are included after the separation of membrane-bound ligand from ligand remaining in solution and prior to quantitation of the amount of ligand bound, *e.g.*, by counting radioactive isotope. The specific binding obtained in the presence of test compound is compared with that obtained in the presence of labeled ligand alone to determine the extent to which the test compound has displaced receptor binding.

[0047] In performing binding assays, artifacts may falsely make it appear that a test compound is interacting with receptor when, in fact, binding is being inhibited by some other

mechanism. Such artefact-generated false signals can be dealt with in a number of ways known to those of skill in the art. For example, the compound being tested can be placed in a buffer which does not itself substantially inhibit the binding of CK β 8-1 to the FPRL-1 receptor, and compounds can be tested at several different concentrations. Preparations of test compounds can be examined for proteolytic activity and antiproteases can be included in assays. Additionally, compounds that are identified as displacing the binding of CK β 8-1 to FPRL-1 receptor can be reexamined in a concentration range sufficient to perform a Scatchard analysis on the results. This type of analysis is well known in the art and can be used for determining the affinity of a test compound for a receptor (see *e.g.*, Ausubel *et al.*, eds., Current Protocols in Molecular Biology, 11.2.1-11.2.19, John Wiley & Sons, New York, NY (1993); Work *et al.*, eds., Laboratory Techniques in Biochemistry and Molecular Biology, NY (1978)). Computer programs can be used to assist in the analysis of results (*e.g.*, Munson, 1983, Methods Enzymol., 92:543-577).

[0048] Depending upon their effect on the activity of the receptor, agents that inhibit the binding of CK β 8-1 to receptor may be either agonists or antagonists. Activation of receptor may be monitored using a number of different methods. For example, phospholipase C assays may be performed by growing cells in wells of a microtiter plate and then incubating the wells in the presence or absence of test compound total inositol phosphates (IP) may then be extracted in resin columns, and resuspended in assay buffer. Assay of IP thus recovered can be carried out using any method for determining IP concentration. Typically, phospholipase C assays are performed separately from binding assays, but it is also possible to perform binding and phospholipase C assays on a single preparation of cells.

[0049] Receptor activation can also be determined based upon a measurement of intracellular calcium concentration. Many types of assays for determining intracellular calcium concentrations are well known to the art and can be employed in the methods of the invention. For example, transformed HEK-293s can be grown to confluence on glass cover slides. After rinsing, the cells can be incubated in the presence of an agent such as Fluo-3, Fluo-4, or FURA-2 AM (Molecular Probes, Eugene, OR). After rinsing and further incubation, calcium displacement can be measured using a photometer.

[0050] Assays that measure the intrinsic activity of the receptor, such as those based upon inositol phosphate measurement, can be used to determine the activity of inverse agonists. Unlike antagonists that block the activity of agonists but produce no activity on their own, inverse agonists produce a biological response diametrically opposed to the response

produced by an agonist. For example, if an agonist promoted an increase in intracellular calcium, an inverse agonist would decrease intracellular calcium levels.

[0051] The radioligand and cell activation assays described herein provide examples of the types of assays that can be used for determining whether a particular test compound alters the binding of CK β 8-1 to the human FPRL-1 receptor and acts as an agonist or antagonist. There are many variations on these assays that are compatible with the present invention. Such assays can involve the use of labeled antibodies as a means for detecting CK β 8-1 that has bound to FPRL-1 receptor or may take the form of the fluorescent imaging plate reader assays.

[0052] The invention is further illustrated by way of the following examples, which are intended to elaborate several embodiments of the invention. These examples are not intended to, nor are they to be construed to, limit the scope of the invention. It will be clear that the invention may be practiced otherwise than as particularly described herein. Numerous modifications and variations of the present invention are possible in view of the teachings herein and, therefore, are within the scope of the invention.

EXAMPLES

Example 1. CK β 8-1 induces mobilization of intracellular Ca²⁺ in FPRL-1 expressing cells.

Expression of human FPRL-1

[0053] HEK-293s cells expressing the G α_{16} protein (Molecular Devices, Sunnyvale, CA), or wild type cells, were transfected with a mammalian expression construct coding for the human FPRL-1 (pGENIRESneo vector) using FuGENE (Roche Diagnostics Corp, Indianapolis, IN). A stable receptor pool of FPRL-1 was developed by applying an antibiotic selection (G418, 1 mg/ml) and the cells were maintained in this selection medium. The expression and functional linkage of FPRL-1 was assessed by assaying the intracellular Ca²⁺ concentration ([Ca²⁺]_i) using W-peptide (Trp-Lys-Tyr-Val-Met-NH₂ (WKYMVM)) (SEQ ID NO:1) or its isoform (Trp-Lys-Tyr-Val-D-Met-NH₂) (WKYMDm) from Phoenix Pharmaceuticals, Inc. (Belmont, CA).

Ligands

[0054] In order to identify the ligand of human FPRL-1, a collection of peptide and non-peptide ligands was obtained from commercial sources (Sigma-Aldrich Corp. (St. Louis, MO), CalBiochem (San Diego, CA), American Peptide Company, Inc. (Sunnyvale, CA),

Bachem Bioscience Inc. (King of Prussia, PA), Sigma-RBI (Natick, MA), R&D Systems (Minneapolis, MN), Phoenix Pharmaceuticals, Inc. (Belmont, CA)). The compounds were dissolved in water/DMSO at 3 μ M and placed in 96-well microplates. A total of 2500 compounds (peptides and non-peptides) were prepared and tested.

Assay

[0055] A functional assay was performed with FLIPR (Fluorescent Imaging Plate Reader, Molecular Devices, Sunnyvale, CA) using the fluorescent calcium indicator Fluo-3 (Molecular Probes, Inc., Eugene, OR) on a 96-well platform. HEK-293s cells expressing the human FPRL-1 receptor (and $G_{\alpha 16}$ protein) or wild type cells only expressing the $G_{\alpha 16}$ protein, were loaded with Fluo-3 as follows. Stable HEK-293s clones expressing FPRL-1 (+ $G_{\alpha 16}$) and parental cells (+ $G_{\alpha 16}$) were plated at a density of 20,000 cells/well in a 96-well plate. On the day of the experiment, the FPRL-1-transfected cells were loaded with fluorescent solution (Dulbecco's modified medium containing 4 μ M Fluo-3 and 20% pluronic acid). The cells were incubated at 37 °C for one hour in a humidified chamber. Following the incubation step, cells were washed five times in Hanks' with 20 mM Hepes and 0.1% BSA (pH 7.4). The cells were analyzed using the FLIPR system to measure the mobilization of intracellular calcium in response to different compounds.

Results

[0056] HEK-293s and CHO cells endogenously express some GPCRs such as bradykinin and PACAP receptors, which were used as internal controls for assays. The background signal was established with all compounds in the parental HEK-293s or CHO cells transfected with the recombinant $G_{\alpha 16}$ or $G_{\alpha i5}$. Cell lines transiently expressing human FPRL-1 were stimulated with compounds, and calcium responses were compared to parental cells. The functional assay with FLIPR gave calcium mobilization through the activation of FPRL-1 expressing cells (see results in Table 1A).

Table 1A.

Ligand	n=1		n=2	
	EC ₅₀	E _{max} *	EC ₅₀	E _{max} *
^a Rec human CK β 8-1(aa46-137)	6.55 nM	12063	0.52 nM	21332
^b Rec human CK β 8-1(aa46-137)	0.43 nM	8478	0.55 nM	6332
^c Rec human CK β 8-1(aa46-137)	0.69 nM	4124	0.14 nM	6327
^d Rec human CK β 8-1(aa46-137)	2.9 nM	4602	2.5 nM	5949
^e W-peptide (Control)	0.57 nM	13252	7.7 nM	13326

^a : HEK-293s cells stably expressing hFPRL-1 in G α_{16} background

^b : HEK-293s transiently expressing hFPRL-1 in G α_{16} background

^c : CHO cells transiently expressing hFPRL-1 in G α_{16} background

^d : CHO cells transiently expressing hFPRL-1 in G α_{qi5} background

^e : HEK-293s transiently expressing hFPRL-1 in G α_{16} background

* : in relative fluorescent units (RFU)

[0057] Additional functional assays with FLIPR and G α_{16} gave calcium mobilization through the activation of FPRL-1 expressing cells in the presence of CK β 8-1 and other reported ligands (Le *et al.*, 2002, Trends Immunol., 10:1-7) (see results in Table 1B).

Table 1B. Summary of pEC₅₀ and pIC₅₀ values of sCK β 8-1 and known FPRL-1 ligands in calcium mobilization assay.

Compound	Intracellular Ca ²⁺ mobilization pEC ₅₀ (n=3)	
	CHO cells	HEK-293s cells
CK β 8-1 (aa46-137)	9.13 \pm 0.02	8.85 \pm 0.07
CK β 8 (aa46-120)	<5.0	inactive
CK β 8-1 (aa22-137)	<5.7	<5.7
CK β 8 (aa22-120)	<5.0	inactive
SHAAG peptide	6.74 \pm 0.23	7.15 \pm 0.23
Amyloid β protein (A β_{42})	6.09 \pm 0.25	<6.0
Serum Amyloid A protein (SAA)	6.88 \pm 0.07	<6.0
Lipoxin A ₄ (LXA ₄)	<6.0	<6.0
Human Prion protein (hPrP)	<6.0	<6.0

W-peptide (WKYMVM)	10.68 ± 0.25	9.56 ± 0.18
W-peptide (WKYMVm)	n.t.	n.t.

[0058] In Table 1B, The pEC₅₀ or pIC₅₀ values are given as mean ± s.e. mean, and were calculated as -log of the EC₅₀ or -log of the IC₅₀ values (50% of the maximal compound effect); n.t. = not tested.

[0059] More than 1300 compounds were tested, including over 77 chemokines. An N-terminally truncated form of recombinant human CKβ8-1 (CKβ8-1 (aa46-137)) (R&D Systems, Minneapolis, MN), and W-peptide, a known FPRL-1 agonist, were the two most potent compounds to elicit a dose-dependent increase in the mobilization of intracellular calcium ([Ca²⁺]_i) response in CHO or HEK-293s cells co-expressing Gα₁₆ protein and FPRL-1 (see Table 1). Compounds reported in Table 1B did not elicit responses in non-transfected CHO or HEK-293s cells expressing either Gα₁₆ protein or other unrelated G-protein-coupled receptors. Moreover, in the absence of Gα₁₆, similar calcium mobilization responses were observed with CKβ8-1 (aa46-137) and W-peptide in CHO cells transiently expressing FPRL-1.

[0060] The results indicated that CKβ8-1 (aa46-137) was interacting with the transiently or stably expressed FPRL-1 receptor. Confirmation of this conclusion was obtained by the observation of a dose-response relationship with CKβ8-1 (aa46-137) in cells transfected with FPRL-1, but not in non-transfected cells or in cells transfected with other orphan receptors.

[0061] Interestingly, the short and long forms of CKβ8 (CKβ8 (aa46-120) and (CKβ8 (aa22-120))), as well as the long form of CKβ8-1 (CKβ8-1 (aa22-137)) (R&D Systems, Minneapolis, MN) displayed low potency (pEC₅₀ <5.7) at FPRL-1 or were inactive (Table 1B).

[0062] These results suggested that the structural determinants of CKβ8-1 specificity for FPRL-1 might be the 17-amino acid peptide at the N-terminus, since the remaining sequence of the molecule is identical to CKβ8. To explore this hypothesis, we synthesized the 17-amino acid peptide (referred to as the "SHAAG peptide"), and determined its potency in cells co-expressing Gα₁₆ and FPRL-1. The SHAAG peptide: ₄₇LWRRKIGPQMTLSHAAG₆₃ (SEQ ID NO:2) (numbered to indicate the amino acid positioning within the CKβ8-1 protein sequence).

[0063] The SHAAG peptide was ~60 to 200 times less potent at FPRL-1 as compared to CKβ8-1 (aa46-137), but ~120 times more potent than the long form, CKβ8-1(aa22-137)



(Table 1). In CHO and HEK-293s cells co-expressing $G_{\alpha_{16}}$ and FPRL-1, other known FPRL-1 ligands (*i.e.*, $A\beta_{42}$, SAA, and hPrP) were ~200- to over 1000-fold less potent at FPRL-1 than CK β 8-1 (aa46-137), in agreement with published results (Le *et al.*, 2002, Trends Immunol., 10:1-7), whereas the LXA₄ observed potency for FPRL-1 was low ($pEC_{50} < 6$).

[0064] To eliminate the possibility that the low potency displayed by the full-length recombinant CK β 8-1 (aa22-137) at FPRL-1 was due to a misfolding during synthesis and/or degradation during the purification process, we measured $[Ca^{2+}]_i$ release in cells stably expressing CCR1, and confirmed the biological activity of the samples used (Table 2).

Table 2. CK β 8-1 (aa22-137) is active on CCR1 stably expressed in HEK-293s cells.

Compound	pEC_{50} (n=4)
CK β 8-1 (22-137)	7.42 ± 0.03
CK β 8-1 (46-137)	8.14 ± 0.19
CK β 8 (22-120)	8.42 ± 0.07
CK β 8 (46-120)	8.88 ± 0.12
RANTES	9.57 ± 0.06

[0065] In Table 2, the pEC_{50} values are given as mean \pm s.e. mean, and were calculated as – log of the EC_{50} values.

[0066] Long forms CK β 8 (aa22-120) and CK β 8-1 (aa22-137) had been shown to potently activate CCR1 (Youn *et al.*, 1998, Blood, 91:3118-3126). RANTES, a CCR1 agonist, produced a pEC_{50} value of 9.57 ± 0.06 , in agreement with published results (Chou *et al.*, 2002, Br. J. Pharmacol., 137:663-675). The rank order of potency of CK β 8, CK β 8-1 and of the N-terminally truncated forms at inducing calcium flux *via* CCR1 was as follows: CK β 8 (aa46-120) > CK β 8 (aa22-120) > CK β 8-1 (aa46-137) > CK β 8-1 (aa22-137) (Table 2).

[0067] These results indicated that, CK β 8-1 (aa22-137) is an active compound, and its potency is ~200 to 300 fold lower at FPRL-1 than, at the CCR1 receptor.

Example 2. FPRL-1 is a $G_{\alpha_{i/o}}$ coupled receptor.

[0068] To determine which G_{α} protein is involved in the stimulation of PLC β by FPRL-1, we tested if the Ca^{2+} mobilization pathway is stimulated by FPRL-1 ligands in parental CHO-K1

cell lines transiently expressing that receptor. Only W-peptide and CK β 8-1 (aa46-137), gave a consistent calcium response. The latter cells, transiently expressing FPRL-1, were treated with pertussis toxin (PTX). Pertussis toxin (PTX) pre-treatment completely abolished the dose-response dependent W-peptide and CK β 8-1-induced Ca^{2+} response, suggesting the involvement of $\text{G}_{\alpha i/o}$ and not $\text{G}_{\alpha q}$ protein in the mobilization of intracellular Ca^{2+} . To assess the viability of cells, SLC1 expressing CHO-K1 cells were treated with PTX and incubated with melanin-concentrating hormone (MCH). In accordance with proposed dual coupling (Saito *et al.*, 1999, Nature, 400:265-269) ($\text{G}_{\alpha i}/\text{G}_{\alpha q}$) PTX treatment partially blocked the MCH-induced Ca^{2+} response.

Example 3. CK β 8-1 (aa46-137) inhibits the adenylyl cyclase pathway.

[0069] To further demonstrate the involvement of $\text{G}_{\alpha i}/\text{G}_{\alpha o}$ protein in FPRL-1 signalling pathway, the inhibition of forskolin-stimulated cAMP accumulation in CHO cells was assessed. CK β 8-1 alone, failed to inhibit basal cAMP levels but did inhibit, in a dose-dependent manner, the forskolin-stimulated cAMP accumulation (see Table 3). The pIC_{50} values for W-peptide and its isoform for inhibition of forskolin-stimulated cAMP accumulation are in accordance with published data (Christophe *et al.*, 2001, J. Biol. Chem., 276:2585-2593). Non-transfected CHO cells, or CHO cells expressing an unrelated GPCR were treated with the same range of agonist concentrations and exhibited no inhibition of cAMP accumulation. CK β 8-1 (aa46-137) and W-peptide yielded similar pIC_{50} values in CHO cells stably expressing FPRL-1. These data confirm that FPRL-1 is a $\text{G}_{\alpha i/o}$ -protein-coupled receptor, and is potentially activated by CK β 8-1.

Table 3. pEC_{50} and pIC_{50} values of CK β 8-1 (aa46-137) and known FPRL-1 ligands in various functional assays.

Compound	Adenylyl cyclase pIC_{50} CHO cells	[^{125}I]-W-peptide (WKYMVM) Displacement pIC_{50} (n=3) CHO cells
CK β 8-1 (aa46-137)	9.02 ± 0.20 (n=4)	7.97 ± 0.04
CK β 8 (aa46-120)	inactive (n=2)	inactive
CK β 8-1 (aa22-137)	n.t.	n.t.

CK β 8 (aa22-120)	n.t.	n.t.
SHAAG peptide	n.t.	n.t.
Amyloid β protein (A β_{42})	6.76; 5.90 (n=2)	inactive
Serum Amyloid A protein (SAA)	6.38; 6.48 (n=2)	<5.52
Lipoxin A ₄ (LXA ₄)	<5.7 (n=2)	inactive
Human Prion protein (hPrP)	inactive (n=2)	inactive
W-peptide (WKYMVM)	10.38 \pm 0.38	7.67 \pm 0.06
W-peptide (WKYMVm)	11.87; 12.19 (n=2)	9.34 \pm 0.08 (Kd)

[0070] The pIC₅₀ values are given as mean \pm s.e. mean, and were calculated as $-\log$ of the IC₅₀ values (50% of the maximal compound effect); n.t. = not tested.

Example 4. Efficient displacement of [¹²⁵I]-W-peptide by CK β 8-1 (aa46-137).

[0071] To characterise the binding properties of CK β 8-1, membranes prepared from CHO cells stably expressing FPRL-1 were incubated with the selective FPRL-1 ligand [¹²⁵I]-WKYMVm (Christophe *et al.*, 2001, J. Biol. Chem, 276:2585-2593). The binding was specific and saturable for FPRL-1 using W-peptide. The observed K_d value for WKYMVm was 9.34 \pm 0.08, and CK β 8-1 was found to be the most effective, non-synthetic, agonist at competitively displacing [¹²⁵I]-WKYMVm (see Table 3), this was followed by SAA with a pIC₅₀ value of <5.52. In agreement with the low potency values observed in the calcium mobilization assay, other tested compounds did not displace the labelled ligand. Collectively, the data presented clearly demonstrate the ability of CK β 8-1 to bind to and activate the FPRL-1 receptor with high efficacy and potency, and supports the role of CK β 8-1 as a physiological and functional ligand for FPRL-1.

Example 5. CK β 8-1 induces calcium flux and chemotaxis in polymorpho-nuclear leukocytes (PMNs).

[0072] Neutrophils play a pivotal role in the innate immune response to infection. Since these cells express FPRL-1, we evaluated the effect of CK β 8-1 (aa46-137) on PMNs calcium mobilization using the FLIPR system. CK β 8-1 dose-dependently increased the mobilization of [Ca²⁺]_i. The rank order of potency for FPRL-1 ligands in PMNs was as follows: W-peptide > CK β 8-1 (aa46-137) \geq MMK-1 (Table 4). Interleukin-8 (IL-8), known to activate

CXCR1 and CXCR2 receptors, induced a dose-dependent calcium response indicating the integrity of the PMNs preparation.

Table 4. $[Ca^{2+}]_i$ mobilization in PMNs was measured in response to ligands shown.

Compound	pEC50
W-peptide	9.58± 0.06 (n=6)
CKβ8-1	7.42 ± 0.08 (n=4)
SAA	<5.7 (n=3)
MMK-1	7.17 ± 0.07 (n=3)
IL-8	8.76 ± 0.24 (n=3)
LXA4	inactive (n=4)
MIP-1α	inactive (n=4)
F-peptide	inactive (n=4)

[0073] The physiological relevance of CKβ8-1 (aa46-137) as a ligand for FPRL-1 was assessed by PMNs chemotaxis experiments. CKβ8-1 (aa46-137), MMK-1 and W-peptide (WKYMVm) induced the migration of PMNs at concentrations ranging from 1 pM to 20 μM. The maximum percentage of cell migration produced by sCKβ8-1 was reached at 1 μM, 12 μM with MMK-1 and 100 nM with W-peptide.

[0074] The cell migration data demonstrates the ability of CKβ8-1 to activate human PMNs and suggests that this activity is mediated *via* FPRL-1 receptor endogenously expressed in these cells. To demonstrate the specificity of CKβ8-1 for FPRL-1, human PMNs were pretreated in the presence or absence of a monoclonal anti-FPRL-1 antibody, and calcium mobilization in response to CKβ8-1 was measured. In PMNs, antibody pretreatment reduced the $[Ca^{2+}]_i$ mobilization by 80-90% when incubated with CKβ8-1 (aa46-137). Similar responses were obtained in HEK-293s cells stably co-expressing $G\alpha_{16}$ and FPRL-1.

[0075] Collectively, the data confirm that the effect produced by CKβ8-1 in human PMNs is mediated by FPRL-1.

[0076] The foregoing examples are meant to illustrate the invention and are not to be construed to limit the invention in any way. Those skilled in the art will recognize modifications that are within the spirit and scope of the invention.

We claim:

1. A method for identifying compounds that modulate binding of CK β 8-1 to FPRL-1 receptor, said method comprising:
 - providing cells expressing FPRL-1 receptor or functional fragment or variant thereof;
 - contacting said cells with CK β 8-1 or a functional fragment or variant thereof, in the presence or absence of a compound; and
 - measuring a signal indicative of receptor activation;where an alteration to said signal in the presence of a compound identifies said compound as a compound that modulates binding of CK β 8-1 to FPRL-1 receptor.
2. The method of claim 1, wherein the FPRL-1 receptor is expressed from a heterologous FPRL-1 receptor gene.
3. The method of claim 1, wherein the FPRL-1 receptor is mammalian.
4. The method of claim 3, wherein the FPRL-1 receptor is human.
5. The method of claim 1, wherein said cells are mammalian cells.
6. The method of claim 5, wherein the cells are human cells.
7. The method of claim 1, wherein said measuring is performed using a FLIPR assay.
8. The method of claim 1, wherein the signal measured is modulation of intracellular phospholipase C activity, intracellular adenylyl cyclase activity or intracellular calcium concentration.
9. The method of claim 1, wherein the CK β 8-1 is CK β 8-1 (aa46-137).
10. A method for identifying compounds that modulate the binding of CK β 8-1 to the FPRL-1 receptor, said method comprising:
 - providing the FPRL-1 receptor or functional fragment or variant thereof;

contacting the FPRL-1 receptor or functional fragment or variant thereof, with CK β 8-1 or functional fragment or variant thereof in the presence or absence of a compound; and

measuring the amount of CK β 8-1 or functional fragment or variant thereof that forms a complex with the FPRL-1 receptor or functional fragment or variant thereof; where an alteration to the amount of said complex formed in the presence of said compound identifies said compound as a compound that modulates binding of CK β 8-1 to the FPRL-1 receptor.

11. The method of claim 10, wherein FPRL-1 receptor/CK β 8-1 complexes are isolated prior to measuring the amount of CK β 8-1 in said complexes.
12. The method of claim 11, wherein the CK β 8-1 is detectably labeled.
13. The method of claim 12, wherein the CK β 8-1 is radiolabeled, fluorescently labeled, or chemiluminescently labeled.
14. The method of claim 13, wherein the CK β 8-1 is radiolabeled.
15. The method of claim 10, wherein CK β 8-1 is bound to an enzyme, and measuring is carried out by enzyme-linked immunosorbent assay (ELISA).
16. The method of claim 10, wherein the FPRL-1 receptor, or functional fragment or variant thereof, is human.
17. The method of claim 10, wherein the CK β 8-1 is CK β 8-1 (aa46-137).
18. The method of claim 10, wherein the FPRL-1 receptor, or functional fragment or variant thereof, is provided as cells expressing the FPRL-1 receptor or functional fragment or variant thereof, or is provided as membranes prepared from said cells.
19. The method of claim 18, wherein the FPRL-1 receptor, or functional fragment or variant thereof, is expressed from a heterologous FPRL-1 receptor gene.

20. The method of claim 18, wherein said cells are mammalian cells.
21. The method of claim 20, wherein the cells are human cells.
22. A method of screening for a FPRL-1 receptor agonist or antagonist comprising measuring a cell stimulating activity through a FPRL-1 receptor determined from the following steps a) and b);
- a) contacting a compound with a cell expressing a FPRL-1 receptor or functional fragment or variant thereof (test screen), and comparing the results to a control screen wherein the cell does not express the FPRL-1 receptor or functional fragment or variant thereof, wherein said compound having cell stimulating activity in the test screen but not the control screen indicates that the test compound is a FPRL-1 receptor agonist,
- b) contacting CK β 8-1 or functional fragment or variant thereof and a test compound with a cell expressing a FPRL-1 receptor or functional fragment or variant thereof (test screen), and comparing the results to a control screen wherein the cell does not express the FPRL-1 receptor or functional fragment or variant thereof, where a decrease in cell stimulating activity by CK β 8-1 or functional fragment or variant thereof in the test screen but not the control screen indicates that the test compound is a FPRL-1 receptor antagonist.
23. The method of claim 22, wherein the CK β 8-1 is CK β 8-1 (aa46-137).
24. The method of claim 23, wherein the cell stimulating activity is intracellular phospholipase C activity, intracellular adenylyl cyclase activity, or intracellular calcium concentration.
25. A method of screening for compounds that modulate binding of CK β 8-1 to FPRL-1 receptor, comprising comparing the amount of CK β 8-1 or functional fragment or variant thereof bound to FPRL-1 receptor or functional fragment or variant thereof in steps a) and b):
- a) contacting CK β 8-1 or functional fragment or variant thereof with the FPRL-1 receptor or functional fragment or variant thereof;
- b) contacting CK β 8-1 or functional fragment or variant thereof and a test compound with the FPRL-1 receptor or functional fragment or variant thereof;

where an alteration in the amount of CK β 8-1 or functional fragment or variant thereof bound to FPRL-1 receptor or functional fragment or variant thereof in step b) indicates that the test compound modulates binding of CK β 8-1 to the FPRL-1 receptor.

26. The method of claim 25, wherein the CK β 8-1 is CK β 8-1 (aa46-137).

27. A method of screening for compounds that inhibit binding of CK β 8-1 to FPRL-1 receptor, comprising comparing the amount of CK β 8-1 or functional fragment or variant thereof bound to FPRL-1 receptor or functional fragment or variant thereof in steps a) and b):

- a) contacting CK β 8-1 or functional fragment or variant thereof with the FPRL-1 receptor or functional fragment or variant thereof;
- b) contacting CK β 8-1 or functional fragment or variant thereof and a test compound with the FPRL-1 receptor or functional fragment or variant thereof;

where a decrease in CK β 8-1 or functional fragment or variant thereof binding in step b) indicates that the test compound inhibits binding of CK β 8-1 to the FPRL-1 receptor.

28. The method of claim 27, wherein the CK β 8-1 is CK β 8-1 (aa46-137).

29. A method of identifying a compound that modulates binding of CK β 8-1 to FPRL-1 receptor, comprising contacting FPRL-1 receptor or functional fragment or variant thereof with CK β 8-1 or functional fragment or variant thereof in the presence or absence of a test compound, and comparing the amount of binding between CK β 8-1 or functional fragment or variant thereof and the FPRL-1 receptor or functional fragment or variant thereof in the presence or absence of the test compound, where an alteration in the amount of binding between CK β 8-1 or functional fragment or variant thereof and the FPRL-1 receptor or functional fragment or variant thereof in the presence of the test compound indicates that the test compound modulates binding between CK β 8-1 and the FPRL-1 receptor.

30. The method of claim 29, wherein the CK β 8-1 is CK β 8-1 (aa46-137).

31. A method of identifying a compound that binds FPRL-1 receptor, comprising incubating a cell expressing FPRL-1 receptor or functional fragment or variant thereof with

CK β 8-1 or functional fragment or variant thereof in the presence or absence of a compound, and detecting displacement of CK β 8-1 or functional fragment or variant thereof binding to the FPRL-1 receptor or functional fragment or variant thereof in the presence of the compound, where displacement of said binding is indicative of a compound that binds the FPRL-1 receptor.

32. The method of claim 31, wherein the CK β 8-1 is CK β 8-1 (aa46-137).

33. A method of determining if a test compound is an agonist, antagonist or inverse agonist of CK β 8-1 comprising

- a) incubating a cell expressing FPRL-1 or functional fragment or variant thereof with the test compound;
- b) measuring a signal indicative of receptor activation; and
- c) comparing the measurement in b) with a second measurement of a signal indicative of receptor activation obtained from incubations performed in the absence of the test compound, where the test compound is an agonist of CK β 8-1 if the signal indicative of receptor activation is higher in the presence of the test compound than in its absence, and wherein the test compound is an antagonist of CK β 8-1 if the signal indicative of receptor activation is lower in the presence of the test compound than in its absence.

INTERNATIONAL SEARCH REPORT

Int. Patent Application No

PCT/GB 03/04132

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/566 G01N33/74

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 03 031603 A (CHEMOCENTRYX INC) 17 April 2003 (2003-04-17) page 4, line 1-9; examples 4,6,7; table 6 page 6, line 3-10 page 27, line 6 -page 29, line 17	1-33
A	YOUN BYUNG S ET AL: "Characterization of CKbeta8 and CKbeta8-1: Two alternatively spliced forms of human beta-chemokine, chemoattractants for neutrophils, monocytes, and lymphocytes, and potent agonists at CC chemokine receptor 1" BLOOD, vol. 91, no. 9, 1 May 1998 (1998-05-01), pages 3118-3126, XP002268293 ISSN: 0006-4971 cited in the application abstract	1-33

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

28 January 2004

Date of mailing of the international search report

19/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Vadot-Van Geldre, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/04132

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01 21188 A. (OPPENHEIM JOOST J ;GONG WANG HUA (US); US HEALTH (US); GAO JI LIAN) 29 March 2001 (2001-03-29) page 38, line 24 -page 39, line 25; claim 7	1-33
A	KLEIN C ET AL: "Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast" NATURE BIOTECHNOLOGY; NATURE PUBLISHING, US, vol. 16, no. 13, December 1998 (1998-12), pages 1334-1337, XP002137534 ISSN: 1087-0156 the whole document	1-33

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 03/04132

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03031603	A	17-04-2003	US 2003096260 A1	22-05-2003
			WO 03031603 A1	17-04-2003
WO 0121188	A	29-03-2001	WO 0121188 A1	29-03-2001
			AU 6395199 A	24-04-2001
			CA 2383172 A1	29-03-2001
			US 2003120037 A1	26-06-2003

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

REVISED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number
WO 2004/027427 A1

- (51) International Patent Classification⁷: **G01N 33/566**
- (21) International Application Number:
PCT/GB2003/004132
- (22) International Filing Date:
19 September 2003 (19.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/412,026 19 September 2002 (19.09.2002) US
- (71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Sodertalje (SE).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): **HENDERSON, Duncan** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **SALTER, Sylvia** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **ELAGOZ, Aram** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Québec H4S 1Z9 (CA). **GRAZZINI, Eric** [FR/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Québec H4S 1Z9 (CA). **LEMBO, Paola, M., C.** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Québec H4S 1Z9 (CA).
- (74) Agent: **ASTRAZENECA AB**; Global Intellectual Property, S-151 85 Sodertalje (SE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the revised international search report:
6 May 2004
- (15) Information about Correction:
see PCT Gazette No. 19/2004 of 6 May 2004, Section II
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ASSAYS FOR FPRL-1 LIGANDS

(57) Abstract: Assays for screening for compounds that act as agonists, antagonists, or inverse agonists of CK β 8-1 at the FPRL-1 receptor.

WO 2004/027427 A1

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/04132

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/566

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 03 031603 A (CHEMOCENTRYX INC) 17 April 2003 (2003-04-17) page 4, line 1-9; examples 4,6,7; table 6 page 6, line 3-10 page 27, line 6 -page 29, line 17	1-33
A	YOUN BYUNG S ET AL: "Characterization of CKbeta8 and CKbeta8-1: Two alternatively spliced forms of human beta-chemokine, chemoattractants for neutrophils, monocytes, and lymphocytes, and potent agonists at CC chemokine receptor 1" BLOOD, vol. 91, no. 9, 1 May 1998 (1998-05-01), pages 3118-3126, XP002268293 ISSN: 0006-4971 cited in the application abstract	1-33

	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

16 March 2004

Date of mailing of the international search report

19. 02. 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Vadot-Van Geldre, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/04132

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01 21188 A (OPPENHEIM JOOST J ;GONG WANG HUA (US); US HEALTH (US); GAO JI LIAN) 29 March 2001 (2001-03-29) page 38, line 24 -page 39, line 25; claim 7 ---	1-33
A	KLEIN C ET AL: "Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast". NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 16, no. 13, December 1998 (1998-12), pages 1334-1337, XP002137534 ISSN: 1087-0156 the whole document -----	1-33

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 03/04132

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03031603	A	17-04-2003	US 2003096260 A1 WO 03031603 A1	22-05-2003 17-04-2003
WO 0121188	A	29-03-2001	WO 0121188 A1 AU 6395199 A CA 2383172 A1 US 2003120037 A1	29-03-2001 24-04-2001 29-03-2001 26-06-2003